1 Clinical course and severity outcome indicators among COVID-19 hospitalized patients
2 in relation to comorbidities distribution: Mexican cohort

3 COVID-19 Hospitalizations in Mexico

4

5 Genny Carrillo^{1*}, Nina Méndez-Domínguez², Kassandra Desire Santos-Zaldivar²,
6 Andrea Rochel-Pérez², Mario Azuela-Morales², Osman Cuevas-Koh², Alberto Álvarez-
7 Baeza²

8

9 ¹ Texas A&M University, School of Public Health, Department of Environmental and
10 Occupational Health, School of Public Health, Texas A&M University, Texas, U.S.A.

11 ² Universidad Marista, School of Medicine, Department of Health Sciences, Mérida,
12 Yucatán, México.

13

14 * Genny Carrillo

15 E-mail: gcarrillo@tamu.edu (GC)

16

17

18

19

20

21

22

23 Abstract

24 Introduction: COVID-19 affected worldwide, causing to date, around 500,000 deaths. In
 25 Mexico, by April 29, the general case fatality was 6.52%, with 11.1% confirmed case
 26 mortality and hospital recovery rate around 72%. Once hospitalized, the odds for
 27 recovery and hospital death rates depend mainly on the patients' comorbidities and age.
 28 In Mexico, triage guidelines use algorithms and risk estimation tools for severity
 29 assessment and decision-making. The study's objective is to analyze the underlying
 30 conditions of patients hospitalized for COVID-19 in Mexico concerning four severity
 31 outcomes.

32 Materials and Methods: Retrospective cohort based on registries of all laboratory-
 33 confirmed patients with the COVID-19 infection that required hospitalization in
 34 Mexico. Independent variables were comorbidities and clinical manifestations.
 35 Dependent variables were four possible severity outcomes: (a) pneumonia, (b)
 36 mechanical ventilation (c) intensive care unit, and (d) death; all of them were coded as
 37 binary

38 Results: We included 69,334 hospitalizations of laboratory-confirmed and hospitalized
 39 patients to June 30, 2020. Patients were 55.29 years, and 62.61% were male. Hospital
 40 mortality among patients aged<15 was 9.11%, 51.99% of those aged >65 died. Male
 41 gender and increasing age predicted every severity outcome. Diabetes and hypertension
 42 predicted every severity outcome significantly. Obesity did not predict mortality, but
 43 CKD, respiratory diseases, cardiopathies were significant predictors.

44 **Conclusion:** Obesity increased the risk for pneumonia, mechanical ventilation, and
 45 intensive care admittance, but it was not a predictor of in-hospital death. Patients with
 46 respiratory diseases were less prone to develop pneumonia, to receive mechanical

47 ventilation and intensive care unit assistance, but they were at higher risk of in-hospital
48 death.

49 **Keywords:** Hospital Mortality; Triage; Mexico; COVID-19; Severe Acute Respiratory

50 Syndrome Coronavirus 2.

51

52

53 Introduction

54 SARS-CoV-2 is in the family of viruses called coronavirus, characterized for
55 causing mild symptoms like the common cold to severe respiratory syndrome (SR) to
56 susceptible humans [1]. As the cause of an emerging highly transmissible agent,
57 COVID-19 was identified as the cause of severe, fatal respiratory disease in Wuhan
58 China by the end of 2019 [2]. By February 28, imported cases were confirmed in
59 Mexico [3].

60 COVID-19 has to date, affected worldwide population involving approximately
61 216 countries, with 11 million confirmed cases and around 500,000 deaths [4]. In
62 Mexico, by April 29, 245,000 confirmed cases, and 29,843 deaths had been reported;
63 based on these data, the national incidence rate was 13.89 / 100,000 inhabitants. General
64 case fatality is 6.52%, and 11.1 % confirmed case mortality and hospital recovery rate
65 around 72%. [3]. Once hospitalized, the odds for recovery and, therefore, the hospital
66 death rates depend mainly on the patients' underlying health conditions and the clinical-
67 pathological manifestations that they may develop.

68 According to epidemiologic data, men are more prone to develop severe cases
69 than women are; smoking abuse may relate to adverse outcomes among COVID-19
70 hospitalized patients [5, 6]. Furthermore, comorbidities have been associated with a
71 higher mortality rate, including hypertension, respiratory diseases, cardiac pathologies,
72 diabetes, and CPK [7-9]. Additionally, smoking habits may relate to adverse outcomes
73 among COVID-19 hospitalized patients due to an overexpression of angiotensin
74 converter enzyme [10]. The mechanical impairment of respiration in COVID-19
75 patients is due to a nervous alteration associated with damage to the solitary and
76 ambiguous tract nuclei. They are responsible for the innervation of the muscles, glands,
77 and blood vessels, causing death due to dysfunction of the cardiorespiratory system [11,

12]. Another cause of mechanical alteration is related to acute respiratory distress syndrome, caused by excessive recruitment of immune cells, producing an increase in pro-inflammatory factors, ending in dysfunction of the pulmonary circulation, and increased cardiac output [13]. Therefore, immune impairment and uncontrolled diabetes may inhibit the proliferation of lymphocytes, monocytes, macrophages, and neutrophils, favoring viral replication, and translating in morbidity that is more significant and mortality proneness [14]. Additionally, patients with long term uncontrolled diabetes may also sum an unknown kidney function impairment.

Obesity is a chronic disease resulting from the storage of energy as fat cells causing hypertrophy and hyperplasia with an increase in adipose tissue and free fatty acids resulting in endocrine and mechanical alteration. The latter is a factor causing dyspnea due to decreased lung volume and ventilator capacity associated with the increased abdominal pressure in the diaphragm [15]. High blood pressure (HBP) and insulin resistance or diabetes often accompanies obesity; therefore, obesity and its associated chronic conditions have more than one pathophysiological pathway of enabling severe manifestations in COVID-19 patients.

Even when asthma has not been identified as a strong risk factor for acquiring coronavirus disease, asthma patients, mainly those poorly controlled, could be at the highest risk of developing severe COVID-19 due to yet unknown immune networks that involve inflammatory cytokines [16]. Acute exacerbations of asthma require early recognition and intervention before a severe and life-threatening course of the condition [17]. Therefore, in the presence of COVID-19, people with asthma may require in-hospital assistance to the possible development of severe outcomes in the acute asthma exacerbations [18]. On the other hand, Chronic Obstructive Pulmonary Disease (COPD) may involve a combination of small airway disease and parenchymal destruction [19]. Therefore, acute exacerbations of COPD may as well derive to respiratory failure that may require treatment with mechanic ventilation in patients in

the intensive care unit (ICU) [20]. The triage strategy for COVID-19 involves and defines the allocation of in-hospital services, intensive therapy management, and even mechanical ventilation with respirators. The triage and risk assessment tools have incorporated questionnaires that estimate the complication's risks, age, gender, gestational status, lifestyle, and chronic comorbidities. Those include obesity, diabetes, hypertension, chronic kidney disease (CKD), cardiopathies, immune impairment, COPD, and asthma. Even when such indicators of complications are based on existing worldwide early evidence, assessing them is vital in clinical practice when deliberating to which patient should need the resource based on the odds of complications or even death.

In Mexico, the health system delivered self-applied risk assessment estimation tools and comprehensive triage guides with clinical practice algorithms. Both kinds of instruments are based on age and comorbidities, which are grouped by the affected system or organ (such as COPD and asthma, grouped as respiratory diseases). That practice may or may not be of independent prognostic importance for hospitalized patients with COVID-19 severe cases [21]. Therefore, analyzing the severity of the events that occurred in hospitalized patients with severe COVID-19 can help to identify the characteristics and comorbidities that represent increased odds for a poor outcome. The objective of the study is to analyze the underlying conditions of patients hospitalized for COVID-19 in Mexico concerning four severity outcomes (a) pneumonia, (b) mechanical ventilation (c) intensive care therapy, and (d) death.

Materials and methods

This study is a retrospective cohort based on the epidemiologic case of all laboratory-confirmed patients with the COVID-19 infection that required hospitalization and complemented with the medical records of in-hospital assistance until discharge. In Mexico during the contingency, public hospitals in all 32 states were reconverted to receive and provide attention to COVID-19 patients specifically, and all hospitalizations

130 derived from COVID-19 were notified mandatorily thru real-time epidemiologic
131 surveillance system with the international classification of diseases under code U07.1.
132 [22]. Ethical approval and Institutional Review Board for this study were exempted by
133 Universidad Marista de Merida Board of Ethics because this study derives from Open
134 Access anonymized dataset provided under the Mexican board of health through its
135 General Directorate of Health Information webpage.

136 A standardized epidemiological case study form for each patient, including
137 comorbid conditions, is generated, including clinical manifestations for triage. The in-
138 hospital clinical course section is added if patients are hospitalized. Once updated,
139 verified, and ratified, case studies are uploaded to the website of the department of
140 health information as open access data sets. For the present study, we used the
141 anonymized, open-access datasets. Data sets were coded, transformed into dependent
142 and independent variables.

143 Independent variables were grouped as sociodemographic, comorbidities, and
144 clinical. The dependent variables represented four possible severity outcomes that
145 occurred during hospitalization including (a) pneumonia, (b) mechanical ventilation (c)
146 intensive care unit, and (d) death; all of them were coded as binary. The frequencies,
147 means, and percentages are presented and compared between groups for severity
148 outcome distribution. The hospitalization rates are presented by 100,000 inhabitants,
149 and for each severity outcome, percentages were calculated, while interstate variability
150 was also assessed for each variable.

151 Severity outcomes were analyzed in separate binary logistic regression models
152 adjusted by age and gender. For statistical significance, a p-value <0.05 was considered
153 significant, while odds ratios were compared to 1.00 as a reference value, where
154 significant values <1.00 were indicators as protective and >1.00 as of increased risk;

155 finally, post hoc tests were performed to assess goodness of fit. All statistical analysis
156 was performed using Stata 15 software.

157

158 **Results**

159 To July 30, 2020, 69,334 patients with laboratory-confirmed SARS-CoV-2
160 infection were hospitalized in Mexican reconverted hospitals; male patients represented
161 62.61%, and the mean age was 55.29 years. Adjusted for age groups, Pediatric patients
162 (age <15) represented 0.11% (N=804) and older adults (age >65) 27% (N=18,780) of
163 hospitalized patients; median hospital stay was of five days. One-fourth of
164 hospitalizations related to patients with obesity (23.56%), more than half of the patients
165 had at least one previously diagnosed comorbidity. Diabetes was present among 30% of
166 all hospitalized patients, hypertension was the most common comorbidity in 34% cases,
167 cardiovascular diseases were present in 0.42%, CPK 0.5%, immune impairment 0.25%,
168 and respiratory diseases 0.56%. Additionally, 0.82% were active smokers, and 1.7%
169 (N=442) of hospitalized women were pregnant.

170 Around two thirds of patients developed pneumonia 66.5% (N=46,107); 9.6%
171 (6,706) received mechanic ventilation; 8.56% (5,937) were located at the ICU and
172 35.72% (N=24,770) died. Regarding the interstate variability, the median rate of
173 hospitalizations per 100,000 inhabitants was 39.7 (Range = 16.4-137.6); the median of
174 pneumonia percentage among hospitalized patients was 63.6 (Range=42.1-79.6), the
175 median of mechanical ventilation percentage was 8.8 (Range=3.3-14.9), the interstate
176 median percentage for intensive care was 9.3 (Range=2.1-28.5), and the median
177 percentage of in-hospital deaths was 33.5 (Range=18.6-47.7). (See supplemental
178 material for maps describing severity outcome distribution in Mexican states).

Table 1 shows the distribution of comorbidities and severity outcomes by age groups of pediatric, young/adults, and the geriatric population. The differences showed how pneumonia affected more than 70% of geriatric patients, young and adult patients had a higher prevalence of obesity; pediatric patients were more commonly assisted at ICU. Death was prevalent in more than half of geriatric patients.

Table 1. Characteristics underlying health conditions among hospitalized with COVID-19 by age group (N=69,334).

Characteristics and underlying health conditions	Age group							
	General		<15		15-65		>65	
	Mean (Standard Deviation)							
Age	55.29	15.98	4.13	4.73	48.93	10.91	74.34	6.66
Days of onset of symptoms *	4.26	3.49	2.04	2.76	4.36	3.49	4.09	3.48
	Percentage (frequency)							
Male	62.62	43,416	64.18	443	62.66	31,697	62.44	11,276
Mechanic ventilation†	9.67	6,706	11.57	93	9.19	4,574	10.86	2,039
Pneumonia	66.5	46,107	39.68	319	65.49	32,583	70.31	13,205
Intensive Care Unit	8.56	5,937	22.29	179	8.32	4,139	8.62	1,619
Active smoking	8.23	5,675	0.37	3	7.92	3,919	9.38	1,753
Pregnancy	1.71	440	-	-	2.45	440	-	-
Obesity	23.61	16,272	3.86	31	25.92	12,814	18.34	3,427
Any comorbidity§	51.06	35,193	10.1	81	44.98	22,243	68.9	12,869
Diabetes	30.92	21,319	2.12	17	28.22	13,962	39.29	7,340
Respiratory disease ¶	5.65	3,902	1.74	14	4.33	2,145	9.32	1,743
Hypertension	34.41	23,737	1.37	11	28.08	13,896	52.59	9,830
Cardiovascular disease **	4.21	2,902	4.73	38	2.7	1,335	8.19	1,529
Chronic kidney disease	4.82	3,322	1	8	4.44	2,199	5.97	1,115
Immune impairment	2.52	1,739	11.5	92	2.33	1,155	2.64	492
Death	35.73	24,770	9.08	73	30.02	14,933	51.99	9,764

Abbreviation: COVID-19 = coronavirus disease 2019; ICU = intensive care unit; CKD = chronic kidney disease.

* Number of days between onset of symptoms and the admission to the care unit.

† Requirement for ventilatory assistance through airway intubation.

§ Presence of any of the following comorbidities: diabetes, respiratory diseases, hypertension, cardiovascular disease, and CKD.
¶ Presence of asthma and/or chronic obstructive pulmonary disease.
** Diagnostic presence of any cardiovascular disease not including hypertension.

When comparing the proportional distribution of comorbidities among patients with or without severity outcomes (Table 2), it is noted that among patients who developed pneumonia, the percentage of active smokers, obesity prevalence, diabetes, hypertension, and cardiovascular diseases were higher than among those who did not develop pneumonia. Proportionally, among patients who needed mechanical ventilation during their hospitalization, pregnancy was less frequent, while obesity, diabetes, hypertension, and cardiovascular diseases were more frequent.

Table 2. Characteristics of comorbidities among COVID-19 hospitalized patients by severity outcomes (N=69,334).

Variables	Pneumonia			Mechanical ventilation			Intensive Care			In-Hospital Death		
	Yes	No	<i>p</i>	Yes	No	<i>P</i>	Yes	No	<i>p</i>	Yes	No	<i>p</i>
Active Smoking	8.68	7.34	<0.001	8.7	8.18	0.072	8.17	8.24	0.43	8.87	7.87	<0.001
Pregnancy	1.05	2.89	<0.001	1.02	1.76	0.005	2.05	1.67	0.111	0.35	2.36	<0.001
Obesity	25.13	20.59	<0.001	28.69	23.07	<0.001	28.73	23.13	<0.001	24.74	22.98	<0.001
Diabetes	32.72	27.34	<0.001	35.72	30.41	<0.001	33.27	30.7	<0.001	37.33	27.36	<0.001
Respiratory disease	5.64	5.67	0.444	5.56	5.66	0.367	5.8	5.64	0.304	6.6	5.13	<0.001
Hypertension	35.72	31.82	<0.001	37.48	34.09	<0.001	34.32	34.42	0.437	42.5	29.93	<0.001
Cardiovascular disease	4.35	3.93	0.005	5.05	4.12	<0.001	4.8	4.15	0.009	5.4	3.55	<0.001
Chronic kidney disease	4.81	4.83	0.46	5.12	4.78	0.115	4.26	4.87	0.019	6.84	3.69	<0.001
Immune impairment	2.51	2.55	0.378	2.63	2.51	0.283	2.91	2.49	0.023	2.89	2.32	<0.001

*Higher proportions of significant difference are presented in bold font.

In the group of patients who received treatment at the intensive care unit, the prevalence of smoking, obesity, cardiovascular diseases, CPK, and immune impairment were significantly higher than those who did not receive treatment at the ICU. Finally, the prevalence of pregnancy was lower in the group of patients who died. Still, the

prevalence of all other comorbidities, including CPK and respiratory diseases (COPD and Asthma) were significantly higher.

After analyzing the association between the comorbidities and the odds for severity outcome occurrence (Table 3), it was found that the male gender and increasing age predicted every severity outcome. Pregnant women were significantly less prone to develop pneumonia and lower risk for in-hospital death. Diabetes and hypertension predicted every severity outcome significantly. Even when obesity increased the risk for pneumonia, more susceptible to receiving mechanical ventilation, and admitted at the ICU, obesity was not a predictor of in-hospital death.

Table 3. Association between comorbidities among hospitalized patients (N=69,334)

Variable	Mean/ Percentage	n	Odds Ratio	Standard Error	z	p	95% Confidence Intervals	
Pneumonia (66.50%, N= 46,107)								
Gender (Male)	63.80	29418	1.17	0.02	9.44	<0.001	1.13	1.21
Age	56.46		1.01	0.00	27.00	<0.001	1.01	1.01
Diabetes	32.72	15001	1.25	0.04	7.51	<0.001	1.18	1.33
Hypertension	35.72	16383	1.19	0.04	5.91	<0.001	1.12	1.26
Cardiac Disease	4.35	1993	1.01	0.07	0.15	0.879	0.89	1.15
Chronic Kidney Disease	4.81	2206	0.93	0.06	-1.15	0.249	0.82	1.05
Immune impairment	2.51	1150	0.99	0.08	-0.08	0.936	0.86	1.15
Pregnancy	1.05	175	0.41	0.04	-8.92	<0.001	0.34	0.50
Active smoking	8.68	3978	1.02	0.07	0.32	0.746	0.90	1.17
Obesity	25.13	11509	1.27	0.04	7.84	<0.001	1.20	1.33
Respiratory disease	5.62	2590	1.00	0.05	-0.06	0.952	0.90	1.10
Mechanic ventilation (9.67%, N=6,706)								
Gender (Male)	67.69	29418	1.29	0.04	9.19	<0.001	1.22	1.36
Age	57.21		1.01	0.00	10.48	<0.001	1.01	1.01
Diabetes	35.72	2355	1.30	0.06	5.29	<0.001	1.18	1.44
Hypertension	37.48	2471	1.16	0.06	2.92	0.004	1.05	1.28

Cardiac Disease	5.05	332	1.10	0.11	0.95	0.340	0.90	1.35
Chronic Kidney Disease	5.12	337	1.04	0.10	0.38	0.706	0.85	1.26
Immune impairment	2.63	173	0.91	0.12	-0.68	0.494	0.70	1.19
Pregnancy	1.02	22	0.67	0.15	-1.79	0.073	0.43	1.04
Active smoking	8.70	573	0.85	0.10	-1.37	0.171	0.67	1.07
Obesity	28.69	1891	1.35	0.07	6.09	<0.001	1.23	1.49
Respiratory disease	5.47	367	0.92	0.08	-0.98	0.326	0.77	1.09
Intensive care Unit (8.56%, N=5,937)								
Gender (Male)	66.96	3,976	1.23	0.04	7.24	<0.001	1.16	1.30
Age	54.99		1.02	0.00	-1.52	0.129	1.02	1.02
Diabetes	37.49	1,950	1.14	0.06	2.39	0.017	1.02	1.26
Hypertension	41.35	2,016	1.01	0.05	0.20	0.841	0.91	1.12
Cardiac Disease	94.73	282	1.13	0.13	1.11	0.269	0.91	1.41
Chronic Kidney Disease	94.88	250	0.92	0.10	-0.71	0.476	0.74	1.15
Immune impairment	96.14	171	1.27	0.16	1.85	0.064	0.99	1.64
Pregnancy	97.96	40	1.32	0.23	1.62	0.106	0.94	1.86
Active smoking	2.04	480	0.73	0.10	-2.26	0.024	0.56	0.96
Obesity	3.19	1686	1.31	0.07	5.14	0.000	1.18	1.46
Respiratory disease	67.52	342	0.97	0.12	-0.23	0.818	0.77	1.23
Death (35.73%, N=24,770)								
Gender (Male)	65.65	16262	1.28	0.02	14.45	<0.001	1.24	1.33
Age	61.11		1.04	0.00	69.37	<0.001	1.04	1.04
Diabetes	37.33	9187	1.39	0.04	11.11	<0.001	1.31	1.47
Hypertension	42.50	10460	1.64	0.05	16.88	<0.001	1.55	1.74
Cardiac Disease	5.40	1329	1.22	0.08	3.11	0.002	1.07	1.38
Chronic Kidney Disease	6.84	1683	1.59	0.09	7.82	<0.001	1.42	1.79
Immune impairment	2.89	710	1.11	0.09	1.41	0.157	0.96	1.29
Pregnancy	0.35	30	0.20	0.04	-8.44	<0.001	0.13	0.29
Active smoking	8.87	2183	0.94	0.07	-0.83	0.407	0.83	1.08
Obesity	24.74	6080	1.05	0.03	1.52	0.127	0.99	1.11
Respiratory disease	6.56	1626	1.17	0.06	3.13	0.002	1.06	1.29

223

224 On the contrary, concerning respiratory diseases (asthma and COPD), patients

225 were not more vulnerable to develop pneumonia. They were not prone to receive

226 mechanical ventilation or assistance at the intensive care unit, but they were at higher

227 risk of hospital death. Finally, *post hoc* analysis and likelihood in the regression model
228 ensured goodness of fit with $p=0.19$.

229

230 Discussion

231 The present study has provided an overview of the severity outcomes among
232 hospitalized patients due to laboratory-confirmed COVID-19 infection in Mexico
233 between February 28 and June 30, 2020. Nationwide, to the studied date, a
234 hospitalization rate of 58.3 per 100,000 inhabitants was observed. By the end of April
235 2020, the in-hospital mortality rate was 27.85%. By July 30, we observed that 33.5%
236 died while assisted in hospitals. The national in-hospital mortality rate increased during
237 May and June.

238 The average age of the population of hospitalized patients in Mexico is between
239 55 years, with males' predominance (62.62%). However, it changes concerning the
240 population. In different studies, the median is at 41 years with a higher proportion in
241 men (56.5%) and a wide range of patients who coexist with some medical comorbidity
242 (12-67%), adding that the prevalence of hypertension (16%), diabetes (10.1%) and
243 respiratory diseases (2%) in other populations was lower in comparison to this study
244 [23]. In a follow-up and surveillance of cases study in the United States, the median was
245 48 years with similar proportions between the genders, thus indicating that the
246 frequencies of comorbidities were different in contrast to this study, since there is a
247 lower rate of patients with diabetes (30.2%) and cardiovascular diseases including
248 hypertension (32.2%) in this population. However, the percentages of patients with
249 respiratory diseases (17.5%), CPK (7.6%), and immunocompromised (5.3%) were
250 higher in comparison to the hospitalized patients in the present study [5].

Concerning the pediatric patients, the average age in our population varies in comparison to other studies that had reported six years as the median age of pediatric patients. However, this differs according to the age range, determined to consider a pediatric patient in systematic reviews [24, 25]. Patel NA reported in a systematic review that the most common underlying clinical conditions in pediatric patients with COVID-19 disease were asthma, immunosuppression, and cardiovascular diseases, this conditions being prevalent in 21% of the patients, however, in our study, only 10% of patients had any comorbidity, adding that there were also cases of patients with diabetes, hypertension and CKD [26]. Concerning mechanical ventilation and ICU admission, the evidence reported that 0.7% of patients avoided both, which is lower than what we found in this study, with 11.57% of patients requiring mechanical ventilator assistance and 22.29% of patients admitted to the ICU. Even when we observed lower mortality (9.08%) among pediatric patients, compared to other groups of patients distributed by age, the pediatric mortality is almost ten times greater than the one reported by Meena J in 4,476 patients, of which five individuals died [27].

In the present study, patients aged >65, had a proportion of death (51.99%) that surpassed the frequency of survival when hospitalized. It is not surprising that all comorbidities were more prevalent among male elderly patients and that every severity outcome was more frequent. Odds of developing pneumonia, receiving mechanical ventilation, being assisted at the ICU, and having a fatal outcome during hospital stay were higher among men and tended to increase with age. These findings are consistent with similar clinical series from China [23, 28]. Still, they are discordant with the conclusions of the Martín-Sanchez, et al. study [29], where advanced age predicted not being admitted at the ICU. These findings from the Spain series may also have

275 underlying explanations from non-clinical nature, partially derived from resource
276 administration and hospital decision-making.

277 Comorbidities distribution among patients in this study is congruent with the
278 high prevalence of chronic diseases among adult Mexican men, which reached 75.2% of
279 the adult population according to the latest national health survey; additionally, 10.3%
280 of the population has diabetes [30]. Mexico has been identified as the second country
281 with the largest population affected by obesity [31].

282 Yang J et al., in their systematic review noted that hypertension and diabetes
283 were the most common comorbidities followed by cardiovascular and respiratory
284 diseases; they also mention that the severity and clinical course of COVID-19 disease
285 were related to these health conditions. Furthermore, Du RH et al. indicate that patients
286 over 65 have a higher risk of dying from the disease [7,32]. In the present study,
287 hypertension and diabetes were also the most common comorbidities among
288 hospitalized patients, and consistent with our results, the advanced age and those with
289 pre-existing cardiovascular disease, were significant predictions of hospital mortality.

290 A study by Vardabas et al. reports that smoking is also associated with a
291 negative progression of the disease since it presents a more significant probability (RR
292 1.4) of showing worsening of the symptoms to 2.4 times the likelihood of requiring
293 mechanical ventilation, admission to the ICU, and risk of death [6]. However, in this
294 study, that was not the case since smoking was not found to be a risk factor for severity
295 outcomes.

296 We have presented how obesity was related to higher odds of developing
297 pneumonia, mechanical ventilation, and assisted in the ICU. Still, we found that obesity
298 was not a predictor of death. To some degree, our findings are similar to those reported
299 by Tamara A, et al. where it was found that obesity predicted mechanical ventilation

and that a higher degree of obesity was a more reliable predictor [33]. Mexican triage guidelines and official national algorithms for clinical practice describe the route of action and clinical care peculiarities of patients with pneumonia, diabetes, immune impairment, and CPK, consisting of individualized, isolated, or ICU management [21].

Based on our findings, we believe that these algorithms may have had a positive impact on patients' decision-making with the mentioned comorbidities. Still, we consider that updates to such guidelines, including specific evaluation for asthma and COPD ungrouped, could benefit Mexican patients. Our findings showed that patients with respiratory conditions did not proportionally receive more frequently mechanical ventilation or admittance to intensive care unit even when they were significantly more susceptible to die, even after adjusting for age and gender.

Limitations

Limitations of the present study derive from its retrospective design: first are those resulting from data obtained from the epidemiologic surveillance system Open Access datasets that may or may not include reporting or coding defects. Nevertheless, all information is validated and ratified at different administrative levels. The study does not allow us to analyze any acute comorbidities that could have happened simultaneously in hospitalized patients. Lastly, as in any other health system with COVID-19 sentinel surveillance, we may have unintentionally excluded patients hospitalized but were not tested for COVID-19.

Implications and recommendations

Clinical practice guidelines, triage instruments, and algorithms have been precise in guiding hospital care for patients with pneumonia, diabetes, immune

325 impairment, and CPK. However, they could still improve hospital assistance and define
326 resource allocation for patients with algorithms for respiratory conditions, including
327 asthma and COPD.

328

329 **Conclusions**

330 Overall, in-hospital mortality in Mexico due to COVID-19 up to June 30 was
331 35.72%; among pediatric patients, it was 9.11%, and more than half of patients aged
332 >65 died. The most common comorbidities were hypertension and diabetes. Male
333 gender, age, hypertension, and diabetes predicted pneumonia, mechanical ventilation,
334 attention in ICU, and death. Obesity increased the odds of pneumonia, of receiving
335 mechanical ventilation and admittance at the ICU, but did not increase death risk.
336 Contrastingly, patients with CPOD and/or asthma had increased risk for death but did
337 not receive mechanical ventilation nor were assisted at the intensive care unit more
338 frequency.

339

340 Author Contributions: G.C., N.M.-D., A.A.-B. Contributed to the conception and design
341 of the manuscript; K.D.S.-Z., A.R.-P., M.A.-M., and O.C.-K. contributed to collection
342 and management of the hospitalizations and the mortality datasets. N.M.-D. and A.A.-B.
343 performed data analysis and interpretation. All authors drafted and revised the
344 manuscript. All authors read and approved the final manuscript and take full
345 responsibility for the manuscript.

346

347 Funding: This research received no external funding.

348 Conflicts of Interest: The authors declare no conflict of interest.

349

350

351

352 **References**

- 353 1. Coronaviridae Study Group of the International Committee on Taxonomy of
354 Viruses. The species Severe acute respiratory syndrome-related coronavirus:
355 classifying 2019-nCoV and naming it SARS-CoV-2. Version 2. Nat Microbiol.
356 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2. PMID:
357 32123347; PMCID: PMC7095448.
- 358 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia
359 outbreak associated with a new coronavirus of probable bat origin. Nature. 2020
360 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
361 PMID: 32015507; PMCID: PMC7095418
- 362 3. Mendez-Dominguez N, Alvarez-Baeza A, Carrillo G. Demographic and Health
363 Indicators in Correlation to Interstate Variability of Incidence, Confirmation,
364 Hospitalization, and Lethality in Mexico: Preliminary Analysis from Imported and
365 Community Acquired Cases during COVID-19 Outbreak. Int J Environ Res Public
366 Health. 2020 Jun 15;17(12):4281. doi: 10.3390/ijerph17124281. PMID: 32549337;
367 PMCID: PMC7344596.
- 368 4. Johns Hopkins University. COVID-19 Dashboard by the Center for Systems
369 Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Cited 15 July
370 2020]. Available from: <https://coronavirus.jhu.edu/map.html>
- 371 5. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et
372 al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30,
373 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765. doi:
374 10.15585/mmwr.mm6924e2. PMID: 32555134; PMCID: PMC7302472.

- 375 6. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the
376 evidence. *Tob Induc Dis*. 2020 Mar 20;18:20. doi: 10.18332/tid/119324. PMID:
377 32206052; PMCID: PMC7083240.
- 378 7. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities
379 and its effects in patients infected with SARS-CoV-2: a systematic review and meta-
380 analysis. *Int J Infect Dis*. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub
381 2020 Mar 12. PMID: 32173574; PMCID: PMC7194638.
- 382 8. Espinosa OA, Zanetti ADS, Antunes EF, Longhi FG, Matos TA, Battaglini PF.
383 Prevalence of comorbidities in patients and mortality cases affected by SARS-
384 CoV2: a systematic review and meta-analysis. *Rev Inst Med Trop Sao Paulo*. 2020
385 Jun 22;62:e43. doi: 10.1590/S1678-9946202062043. PMID: 32578683; PMCID:
386 PMC7310609.
- 387 9. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in Patients with Liver
388 and Kidney Diseases: An Early Systematic Review and Meta-Analysis. *Trop Med*
389 *Infect Dis*. 2020 May 15;5(2):80. doi: 10.3390/tropicalmed5020080. PMID:
390 32429038; PMCID: PMC7345004.
- 391 10. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in
392 hypertensive cohort and controversies with renin angiotensin system blockers.
393 *Diabetes Metab Syndr*. 2020 Apr 9;14(4):283-287. doi: 10.1016/j.dsx.2020.03.016.
394 Epub ahead of print. PMID: 32283499; PMCID: PMC7144598.
- 395 11. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may
396 play a role in the respiratory failure of COVID-19 patients. *J Med Virol*. 2020
397 Jun;92(6):552-555. doi: 10.1002/jmv.25728. Epub 2020 Mar 11. PMID: 32104915;
398 PMCID: PMC7228394.

- 399 12. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system
400 involvement after infection with COVID-19 and other coronaviruses. Brain Behav
401 Immun. 2020 Jul;87:18-22. doi: 10.1016/j.bbi.2020.03.031. Epub 2020 Mar 30.
402 PMID: 32240762; PMCID: PMC7146689.
- 403 13. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia
404 outbreak associated with a new coronavirus of probable bat origin. Nature. 2020
405 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
406 PMID: 32015507; PMCID: PMC7095418
- 407 14. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge
408 in progress. Diabetes Res Clin Pract. 2020 Apr;162:108142. doi:
409 10.1016/j.diabres.2020.108142. Epub 2020 Apr 9. PMID: 32278764; PMCID:
410 PMC7144611.
- 411 15. Bray GA. Risks of obesity. Endocrinol Metab Clin North Am. 2003 Dec;32(4):787-
412 804, viii. doi: 10.1016/s0889-8529(03)00067-7
- 413 16. Sajuthi SP, DeFord P, Jackson ND, Montgomery MT, Everman JL, Rios CL, et al.
414 Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene
415 expression in the airway epithelium. bioRxiv [Preprint]. 2020 Apr
416 10:2020.04.09.034454. doi: 10.1101/2020.04.09.034454.
- 417 17. Global Initiative for Asthma. Global Strategy for Asthma Management and
418 Prevention, 2020. [Cited 15 July 2020]. Available from: <https://ginasthma.org/>
- 419 18. Mahdavinia M, Foster KJ, Jauregui E, Moore D, Adnan D, Andy-Nweye AB, et al.
420 Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract. 2020 Jul-
421 Aug;8(7):2388-2391. doi: 10.1016/j.jaip.2020.05.006. Epub 2020 May 14. PMID:
422 32417445; PMCID: PMC7224651.

- 423 19. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the
424 diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease.
425 2020 Report. [Cited 15 July 2020]. Available from: <https://goldcopd.org/>
- 426 20. Dixit D, Bridgeman MB, Andrews LB, Narayanan N, Radbel J, Parikh A,
427 Sunderram J. Acute exacerbations of chronic obstructive pulmonary disease:
428 diagnosis, management, and prevention in critically ill patients. *Pharmacotherapy*.
429 2015 Jun;35(6):631-48. doi: 10.1002/phar.1599.
- 430 21. Instituto Mexicano del Seguro Social. Algoritmos interinos para la atención del
431 COVID-19. Actualización del 25 de Junio del 2020. [Cited 15 July 2020]. Available
432 from:
433 [http://educacionensalud.imss.gob.mx/es/system/files/Algoritmos_interinos_COVID](http://educacionensalud.imss.gob.mx/es/system/files/Algoritmos_interinos_COVID_19_CTEC.pdf)
434 [19_CTEC.pdf](http://educacionensalud.imss.gob.mx/es/system/files/Algoritmos_interinos_COVID_19_CTEC.pdf)
- 435 22. World Health Organization. COVID-19 coding in ICD-10. [Accessed: 15th of July].
436 2020. Available at: [https://www.who.int/classifications/icd/COVID-19-coding-](https://www.who.int/classifications/icd/COVID-19-coding-icd10.pdf?ua=1)
437 [icd10.pdf?ua=1](https://www.who.int/classifications/icd/COVID-19-coding-icd10.pdf?ua=1)
- 438 23. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics
439 of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-
440 analysis. *J Infect*. 2020 Jun;80(6):656-665. doi: 10.1016/j.jinf.2020.03.041. Epub
441 2020 Apr 10. PMID: 32283155; PMCID: PMC7151416.
- 442 24. Du H, Dong X, Zhang JJ, Cao YY, Akdis M, Huang PQ, et al. Clinical
443 characteristics of 182 pediatric COVID-19 patients with different severities and
444 allergic status. *Allergy*. 2020 Jun 10;10.1111/all.14452. doi: 10.1111/all.14452.
445 Epub ahead of print. PMID: 32524611; PMCID: PMC7307120.
- 446 25. de Souza TH, Nadal JA, Nogueira RJN, Pereira RM, Brandão MB. Clinical
447 manifestations of children with COVID-19: A systematic review. *Pediatr Pulmonol*.

448 2020 Jun 3:10.1002/ppul.24885. doi: 10.1002/ppul.24885. Epub ahead of print.
 449 PMID: 32492251; PMCID: PMC7300659.

450 26. Patel NA. Pediatric COVID-19: Systematic review of the literature. Am J
 451 Otolaryngol. 2020 Jun 6;41(5):102573. doi: 10.1016/j.amjoto.2020.102573. Epub
 452 ahead of print. PMID: 32531620.

453 27. Meena J, Yadav J, Saini L, Yadav A, Kumar J. Clinical Features and Outcome of
 454 SARS-CoV-2 Infection in Children: A Systematic Review and Meta-analysis.
 455 Indian Pediatr. 2020 Jun 24:S097475591600203. Epub ahead of print. PMID:
 456 32583808.

457 28. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of
 458 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-
 459 centered, retrospective, observational study. Lancet Respir Med. 2020
 460 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
 461 Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26. PMID: 32105632; PMCID:
 462 PMC7102538.

463 29. Martín-Sánchez FJ, Del Toro E, Cardassay E, Valls Carbó A, Cuesta F, Vigara M, et
 464 al. Clinical presentation and outcome across age categories among patients with
 465 COVID-19 admitted to a Spanish Emergency Department. Eur Geriatr Med. 2020
 466 Jul 16. doi: 10.1007/s41999-020-00359-2. Epub ahead of print. PMID: 32671732.

467 30. Secretaría de Salud, Instituto Nacional de Salud Pública, Instituto Nacional de
 468 Estadística y Geografía. Encuesta Nacional de Salud y Nutrición (ENSANUT) 2018.
 469 [Cited 15 July 2020]. Available from:
 470 <https://ensanut.insp.mx/encuestas/ensanut2018/informes.php>

- 471 31. Organisation for Economic Co-operation and Development. Obesity update 2017.
472 [Cited 15 July 2020]. Available from: [https://www.oecd.org/els/health-](https://www.oecd.org/els/health-systems/Obesity-Update2017.pdf)
473 [systems/Obesity-Update2017.pdf](https://www.oecd.org/els/health-systems/Obesity-Update2017.pdf)
- 474 32. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality
475 for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective
476 cohort study. Eur Respir J. 2020 May 7;55(5):2000524. doi:
477 10.1183/13993003.00524-2020. PMID: 32269088; PMCID: PMC7144257.
- 478 33. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19:
479 A systematic review. Diabetes Metab Syndr. 2020 May 12;14(4):655-659. doi:
480 10.1016/j.dsx.2020.05.020. Epub ahead of print. PMID: 32438328; PMCID:
481 PMC7217103.